P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series
Tom Holvoet(Ghent University Hospital), Triana Lobatón, Hannah Gordon(University of Oxford), David Drobne, Bram Verstockt(Universitair Ziekenhuis Leuven), Piotr Eder(Poznan University of Medical Sciences), Sophie Vieujean(Centre Hospitalier Universitaire de Liège), Luís Menchén(Universidad Complutense de Madrid), Assaf Issachar(Tel Aviv University), Pál Miheller(Semmelweis University), Matthias Lenfant(KU Leuven), Edoardo Savarino(University of Padua), Dominik Bettenworth(University Hospital Münster), Davide Giuseppe Ribaldone(University of Turin), Tamás Molnár(University of Szeged), Avnesh S. Thakor(Cambridge University Hospitals NHS Foundation Trust), Ingrid Candel(Hospital Italiano de Buenos Aires), Mette Julsgaard(Aarhus University Hospital)
Cited by 4
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k